Brokerages expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to announce earnings of ($0.44) per share for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Tandem Diabetes Care’s earnings. The highest EPS estimate is ($0.38) and the lowest is ($0.61). Tandem Diabetes Care reported earnings of ($0.97) per share in the same quarter last year, which would suggest a positive year over year growth rate of 54.6%. The firm is expected to announce its next quarterly earnings report on Tuesday, November 7th.

According to Zacks, analysts expect that Tandem Diabetes Care will report full-year earnings of ($1.82) per share for the current fiscal year, with EPS estimates ranging from ($2.40) to ($1.46). For the next fiscal year, analysts forecast that the company will report earnings of ($1.21) per share, with EPS estimates ranging from ($2.18) to ($0.76). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, July 27th. The medical device company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.04. The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $21.74 million. The firm’s revenue was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.60) EPS.

TNDM has been the topic of several research reports. Zacks Investment Research cut Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. B. Riley reaffirmed a “neutral” rating and set a $1.50 price objective on shares of Tandem Diabetes Care in a research report on Friday, April 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $4.71.

Hedge funds have recently modified their holdings of the company. Frontier Capital Management Co. LLC boosted its stake in shares of Tandem Diabetes Care by 348.5% in the first quarter. Frontier Capital Management Co. LLC now owns 4,901,870 shares of the medical device company’s stock worth $5,882,000 after buying an additional 3,808,950 shares in the last quarter. Paulson & CO. Inc. bought a new stake in shares of Tandem Diabetes Care during the first quarter worth approximately $600,000. Bank of America Corp DE boosted its stake in shares of Tandem Diabetes Care by 88.6% in the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after buying an additional 404,452 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Tandem Diabetes Care during the first quarter worth approximately $360,000. Finally, Falcon Point Capital LLC bought a new stake in shares of Tandem Diabetes Care during the first quarter worth approximately $313,000. 45.22% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Tandem Diabetes Care (NASDAQ TNDM) traded down 2.9934% on Wednesday, reaching $0.7324. The company’s stock had a trading volume of 4,430,632 shares. Tandem Diabetes Care has a 12-month low of $0.39 and a 12-month high of $8.81. The company’s 50 day moving average price is $0.61 and its 200 day moving average price is $1.22. The company’s market cap is $36.79 million.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/16/tandem-diabetes-care-inc-tndm-expected-to-post-earnings-of-0-44-per-share.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc and related companies with MarketBeat.com's FREE daily email newsletter.